# Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

> **NCT04257448** · PHASE1,PHASE2 · COMPLETED · sponsor: **GWT-TUD GmbH** · enrollment: 75 (actual)

## Conditions studied

- Pancreas Cancer
- Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** Azacitidine
- **DRUG:** nab-Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Durvalumab
- **DRUG:** Lenalidomide capsule

## Key facts

- **NCT ID:** NCT04257448
- **Lead sponsor:** GWT-TUD GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-25
- **Primary completion:** 2024-07-02
- **Final completion:** 2024-07-02
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-09-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04257448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04257448, "Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04257448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*